Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "hepatitis"

67 News Found

FDA approves AbbVie’s mavyret as first and only treatment for acute hepatitis C
Drug Approval | June 13, 2025

FDA approves AbbVie’s mavyret as first and only treatment for acute hepatitis C

Now approved for both acute and chronic HCV in adults and children aged 3 and above


'Illness To Wellness’ joins hands with ILBS to generate awareness against Hepatitis B patients
News | March 23, 2024

'Illness To Wellness’ joins hands with ILBS to generate awareness against Hepatitis B patients

Hepatitis B infects over 40 million people in India


Roche expands hepatitis diagnostics portfolio
Clinical Trials | November 29, 2023

Roche expands hepatitis diagnostics portfolio

Almost 300 million people globally have chronic hepatitis B


Roche launches Elecsys HCV Duo immunoassay for hepatitis C virus
News | July 20, 2022

Roche launches Elecsys HCV Duo immunoassay for hepatitis C virus

Elecsys HCV Duo is the first commercially available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status.


Saraq Hepatitis C kit receives CDSCO nod
Drug Approval | April 21, 2022

Saraq Hepatitis C kit receives CDSCO nod

The approval of this important test marks the 14th IVD to receive clearance by the CDSCO, and strengthens the company’s foundation for future growth


VBI’s 3-antigen Hepatitis B vaccine gets CHMP nod
Biotech | February 27, 2022

VBI’s 3-antigen Hepatitis B vaccine gets CHMP nod

If approved, PreHevbri will be the only approved 3-antigen hepatitis B vaccine for adults in the E.U.


Aldeyra refocuses pipeline on next-gen RASP modulators despite positive phase II success
Clinical Trials | October 31, 2025

Aldeyra refocuses pipeline on next-gen RASP modulators despite positive phase II success

ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia


Novo Nordisk to acquire Akero Therapeutics for $5.2 billion
News | October 12, 2025

Novo Nordisk to acquire Akero Therapeutics for $5.2 billion

Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases


Novo Nordisk's Wegovy approved in the US for the treatment of MASH
News | August 19, 2025

Novo Nordisk's Wegovy approved in the US for the treatment of MASH

The accelerated approval is supported by results from part 1 of the ESSENCE trial